|1.||Mehran, Roxana: 73 articles (11/2015 - 09/2005)|
|2.||Stone, Gregg W: 71 articles (04/2015 - 09/2005)|
|3.||Lincoff, A Michael: 39 articles (05/2014 - 05/2002)|
|4.||White, Harvey D: 32 articles (03/2015 - 02/2002)|
|5.||Feit, Frederick: 27 articles (12/2014 - 02/2003)|
|6.||Lansky, Alexandra J: 25 articles (02/2015 - 05/2006)|
|7.||Ohman, E Magnus: 23 articles (12/2014 - 09/2004)|
|8.||Waksman, Ron: 23 articles (09/2014 - 11/2003)|
|9.||Witzenbichler, Bernhard: 21 articles (02/2015 - 05/2008)|
|10.||Parise, Helen: 21 articles (12/2014 - 05/2008)|
12/01/2013 - "Bivalirudin was associated with a dramatically reduced risk of bleeding across all categories of renal dysfunction. "
03/01/2013 - "The primary purpose of this analysis is to evaluate the hypothesis that the reduction of in-hospital bleeding is the most plausible explanation for the improved survival of STEMI patients treated with bivalirudin during primary PCI. "
12/01/2005 - "Bivalirudin provides excellent ischemic protection with a significant reduction of bleeding complications, even in high-risk subgroups."
06/01/2004 - "These results suggest that bivalirudin may be used effectively in patients at very high risk of bleeding with enhanced procedural safety."
05/01/2015 - "In present meta-analysis, among patients undergoing PCI, bivalirudin, as compared with UFH, is associated with a significant reduction in major bleeding complications that, however, does not translate into mortality benefits. "
|2.||Acute Coronary Syndrome
08/01/2009 - "The objective was to assess the safety and efficacy of bivalirudin monotherapy in patients with high-risk acute coronary syndrome (ACS) presenting to the emergency department (ED). "
01/01/2008 - "In summary, is has been shown that bivalirudin alone is safe and effective in the vast majority of patients suffering from acute coronary syndromes and being treated invasively. "
01/01/2012 - "Randomized trials show improved outcomes among acute coronary syndrome patients treated with bivalirudin. "
01/01/2008 - "Recent trials (ACUITY and HORIZONS studies) added evidence regarding safety and efficacy of bivalirudin use in acute coronary syndromes. "
01/01/2008 - "Safety and efficacy of bivalirudin in acute coronary syndromes."
01/01/2012 - "Bivalirudin therapy is associated with improved clinical and economic outcomes in ST-elevation myocardial infarction patients undergoing percutaneous coronary intervention: results from an observational database."
12/01/2014 - "The effectiveness of bivalirudin in patients undergoing percutaneous coronary intervention for acute myocardial infarction has been tested in clinical trials, but its use in a real-world scenario has never been reported. "
09/21/2014 - "In the EUROMAX study, 2198 patients with ST-segment elevation myocardial infarction (STEMI) were randomized during transport for primary PCI to bivalirudin or to heparins with optional GPI. "
10/01/2013 - "Leukocyte count is a modulating factor for the mortality benefit of bivalirudin in ST-segment-elevation acute myocardial infarction: the HORIZONS-AMI trial."
04/01/2012 - "Bivalirudin for primary percutaneous coronary intervention in acute myocardial infarction: the HORIZONS-AMI trial."
10/01/2008 - "In the bolus bivalirudin group the mean thrombus weight was significantly greater than in all other groups (p-value < 0.01 in all analyses). "
03/01/2015 - "The present study showed similar residual thrombus burden and angiographic indices of MVO immediately after PCI between patients treated with bivalirudin and those treated with UFH."
08/01/2007 - "Pilot dose-finding and safety study of bivalirudin in infants <6 months of age with thrombosis."
03/01/2015 - "Patients in the bivalirudin group showed lower proportion of white thrombus (55.5% vs. 78.6%, P = 0.016). "
03/01/2015 - "Patients treated with bivalirudin showed similar thrombus volume (0.14 mm(3) [0.00-0.88] vs. 0.13 mm(3) [0.00-0.63], P = 0.962), thrombus score (10 [0-25] vs. 8 [0-21], P = 0.849) and thrombus length (1.70 mm [0.00-4.10] vs. 1.40 mm [0.00-4.05], P = 0.968], as compared with patients treated with UFH. "
03/01/2002 - "In this preliminary study, the strategy of bivalirudin bolus anticoagulation, immediate sheath removal, and 2-hr ambulation after PCI appeared safe, with same-day discharge possible in 26% of unselected patients with stable or unstable angina."
01/01/2002 - "Data from dose-finding studies indicate bivalirudin has potential in the treatment of patients with unstable angina not undergoing percutaneous coronary intervention (PCI); however, well designed comparative studies are needed before firm conclusions can be made. "
08/15/1995 - "Hirulog in the treatment of unstable angina. "
10/01/1993 - "In unstable angina patients, Hirulog infusions quickly and reproducibly yield stable, dose-dependent anticoagulant and antithrombotic effects with a favorable clinical efficacy profile."
10/01/1993 - "A total of 55 patients in the acute phase of unstable angina received intravenous Hirulog according to one of two protocols. "
|4.||Platelet Membrane Glycoprotein IIb
|6.||Low-Molecular-Weight Heparin (Heparin, Low Molecular Weight)
|2.||Angioplasty (Angioplasty, Transluminal)
|3.||Drug Therapy (Chemotherapy)
|5.||Coronary Balloon Angioplasty (Percutaneous Transluminal Coronary Angioplasty)